Latest & greatest articles for irritable bowel syndrome

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on irritable bowel syndrome or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on irritable bowel syndrome and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for irritable bowel syndrome

101. Selective serotonin reuptake inhibitors for the management of irritable bowel syndrome: a meta-analysis of randomized controlled trials

Selective serotonin reuptake inhibitors for the management of irritable bowel syndrome: a meta-analysis of randomized controlled trials Selective serotonin reuptake inhibitors for the management of irritable bowel syndrome: a meta-analysis of randomized controlled trials Selective serotonin reuptake inhibitors for the management of irritable bowel syndrome: a meta-analysis of randomized controlled trials Rahimi R, Nikfar S, Abdollahi M CRD summary The authors stated (...) that there was no statistically significant evidence that selective serotonin reuptake inhibitors (SSRIs) improved abdominal pain, bloating or irritable bowel syndrome (IBS) symptoms, although there was a trend for improvement in abdominal pain. In view of methodological limitations in the review, in particular the failure to adequately address heterogeneity, the conclusions may not be reliable. Authors' objectives To determine the efficacy of selective serotonin reuptake inhibitors (SSRIs) for irritable bowel syndrome (IBS

DARE.2008

102. Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms?

Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms? Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms? Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms? Ford A C, Talley N J, Velhuyzen van Zenten (...) S J, Vakil N B, Simel D L, Moayyedi P CRD summary This review assessed the ability of components of clinical history and physical examination (alone or in combination) to predict a diagnosis of irritable bowel syndrome (IBS) without full investigation of the lower GI tract. The authors' conclusion that individual symptoms and existing diagnostic criteria have only moderate accuracy was a reasonable interpretation of the limited data available. Authors' objectives To determine the accuracy

DARE.2008

103. Effectiveness of probiotics in the treatment of irritable bowel syndrome

Effectiveness of probiotics in the treatment of irritable bowel syndrome Effectiveness of probiotics in the treatment of irritable bowel syndrome Effectiveness of probiotics in the treatment of irritable bowel syndrome Wilhelm S M, Brubaker C M, Varcak E A, Kale-Pradhan P B CRD summary The authors concluded that probiotics may improve symptoms in patients with irritable bowel syndrome, but that benefits were uncertain and further research was required. The authors’ cautious conclusion appeared (...) to reflect the evidence presented, but the limited search, lack of reporting of review methods and an incomplete validity assessment made it difficult to comment on reliability. Authors' objectives To evaluate the effectiveness of probiotics in providing global relief in patients with irritable bowel syndrome (IBS). Searching MEDLINE was searched from inception to October 2007. Search terms were reported. In addition, reference lists of articles were screened. Study selection Blinded, placebo-controlled

DARE.2008

104. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis

Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis Ford A C, Talley N J, Spiegel B M, Foxx-Orenstein A E, Schiller L, Quigley E M, Moayyedi P CRD (...) summary This review concluded that fibre, antispasmodics and peppermint oil are more effective than placebo for treating irritable bowel syndrome. Overall, although the review was generally well conducted, the authors' analyses should be interpreted with caution given their reliance on an often limited number of small and sometimes potentially quite different studies. Authors' objectives To compare the effectiveness of fibre, antispasmodics and peppermint oil with placebo or control for treating

DARE.2008

105. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials

Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo (...) -controlled, 12-week trials Rahimi R, Nikfar S, Abdollahi M CRD summary This review concluded that alosetron was an effective treatment for irritable bowel syndrome when compared to placebo. Participants were predominantly women with diarrhoea-dominant irritable bowel syndrome, so the review findings may be only applicable to this group of patients. Overall, this was a well-conducted review and the authors' conclusions are likely to be reliable. Authors' objectives To evaluate the efficacy

DARE.2008

106. Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials

Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom (...) relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials Andresen V, Montori VM, Keller J, West CP, Layer P, Camilleri M CRD summary This review evaluated the effectiveness of 5-hydroxytryptamine (serotonin) antagonists in treating irritable bowel syndrome (IBS). The authors concluded that 5-hydroxytryptamine antagonists significantly improved symptoms of non-constipated IBS and diarrhoea predominant IBS in men and women

DARE.2008

107. Meta-analysis of probiotics for the treatment of irritable bowel syndrome

Meta-analysis of probiotics for the treatment of irritable bowel syndrome Meta-analysis of probiotics for the treatment of irritable bowel syndrome Meta-analysis of probiotics for the treatment of irritable bowel syndrome McFarland LV, Dublin S CRD summary This review concluded that probiotic use may be associated with improvement in irritable bowel syndrome symptoms compared to placebo, but these results should be interpreted with caution. This cautious conclusion accurately reflects (...) the nature of the evidence and the results of the review, and appears likely to be reliable. Authors' objectives To determine the overall efficacy of probiotics in the treatment of irritable bowel syndrome (IBS). Searching MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL), and C databases and Google Scholar were searched. Reference lists of identified studies, reviews, commentaries, books and meeting abstracts were searched. Search terms were reported. Studies published in full

DARE.2008

108. Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome--multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting

Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome--multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting 18284648 2008 04 02 2008 07 10 2016 11 24 1365-2036 27 9 2008 May Alimentary pharmacology & therapeutics Aliment. Pharmacol. Ther. Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome--multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting (...) . 830-7 10.1111/j.1365-2036.2008.03649.x Relatively few pharmacological treatment options are available for treating patients with irritable bowel syndrome. New and effective medicines are urgently required. To identify an appropriate dosage of renzapride (a 5-HT(4) receptor full agonist/5-HT(3) receptor antagonist) to treat abdominal pain/discomfort in patients with constipation-predominant irritable bowel syndrome. In this randomized, placebo-controlled, phase IIb study in the primary care setting

EvidenceUpdates2008

109. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome.

Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. 18390493 2008 05 05 2008 05 19 2016 12 15 1756-1833 336 7651 2008 May 03 BMJ (Clinical research ed.) BMJ Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. 999-1003 10.1136/bmj.39524.439618.25 To investigate whether placebo effects can experimentally be separated into the response to three components-assessment and observation, a therapeutic (...) ritual (placebo treatment), and a supportive patient-practitioner relationship-and then progressively combined to produce incremental clinical improvement in patients with irritable bowel syndrome. To assess the relative magnitude of these components. A six week single blind three arm randomised controlled trial. Academic medical centre. 262 adults (76% women), mean (SD) age 39 (14), diagnosed by Rome II criteria for and with a score of > or =150 on the symptom severity scale. For three weeks either

BMJ2008 Full Text: Link to full Text with Trip Pro

110. Irritable bowel syndrome in adults: diagnosis and management

Irritable bowel syndrome in adults: diagnosis and management Irritable bowel syndrome in adults: Irritable bowel syndrome in adults: diagnosis and management diagnosis and management Clinical guideline Published: 23 February 2008 nice.org.uk/guidance/cg61 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived (...) be interpreted in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Irritable bowel syndrome in adults: diagnosis and management (CG61) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2

National Institute for Health and Clinical Excellence - Clinical Guidelines2008

111. Hypnotherapy for Children With Functional Abdominal Pain or Irritable Bowel Syndrome: A Randomized Controlled Trial.

Hypnotherapy for Children With Functional Abdominal Pain or Irritable Bowel Syndrome: A Randomized Controlled Trial. BACKGROUND & AIMS: Functional abdominal pain (FAP) and irritable bowel syndrome (IBS) are highly prevalent in childhood. A substantial proportion of patients continues to experience long-lasting symptoms. Gut-directed hypnotherapy (HT) has been shown to be highly effective in the treatment of adult IBS patients. We undertook a randomized controlled trial and compared clinical (...) effectiveness of HT with standard medical therapy (SMT) in children with FAP or IBS. METHODS: Fifty-three pediatric patients, age 8-18 years, with FAP (n = 31) or IBS (n = 22), were randomized to either HT or SMT. Hypnotherapy consisted of 6 sessions over a 3-month period. Patients in the SMT group received standard medical care and 6 sessions of supportive therapy. Pain intensity, pain frequency, and associated symptoms were scored in weekly standardized abdominal pain diaries at baseline, during therapy

EvidenceUpdates2007

112. Hypnotherapy for treatment of irritable bowel syndrome.

Hypnotherapy for treatment of irritable bowel syndrome. BACKGROUND: Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder of unknown aetiology. Current pharmacological treatments have limited value. Hypnotherapy has been reported to have beneficial effects for IBS symptoms. OBJECTIVES: To evaluate the efficacy of hypnotherapy for the treatment of irritable bowel syndrome. SEARCH STRATEGY: Published and unpublished randomised clinical trials and quasi (...) and quasi-randomised clinical studies comparing hypnotherapy for the treatment of irritable bowel syndrome with no treatment or another therapeutic intervention. DATA COLLECTION AND ANALYSIS: All studies were evaluated for eligibility for inclusion. Included studies were assessed for quality and data were extracted independently by four authors. The primary outcome measure of interest was the overall bowel symptom severity score which combines abdominal pain, diarrhoea or constipation and bloating

Cochrane2007

113. Economic evaluation of tegaserod vs placebo in the treatment of patients with irritable bowel syndrome: an analysis of the TENOR study

Economic evaluation of tegaserod vs placebo in the treatment of patients with irritable bowel syndrome: an analysis of the TENOR study Economic evaluation of tegaserod vs placebo in the treatment of patients with irritable bowel syndrome: an analysis of the TENOR study Economic evaluation of tegaserod vs placebo in the treatment of patients with irritable bowel syndrome: an analysis of the TENOR study Bracco A, Jonsson B, Ricci J F, Drummond M, Nyhlin H Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared the use of tegaserod (6 mg twice daily) with placebo for the treatment of irritable bowel syndrome (IBS). Tegaserod, a 5-HT4 receptor partial agonist and promotility agent, addresses the multiple symptoms of IBS

NHS Economic Evaluation Database.2007

115. Cognitive behavioural therapy in addition to antispasmodic therapy for irritable bowel syndrome in primary care: a randomised controlled trial

Cognitive behavioural therapy in addition to antispasmodic therapy for irritable bowel syndrome in primary care: a randomised controlled trial Cognitive behavioural therapy in addition to antispasmodic therapy for irritable bowel syndrome in primary care: a randomised controlled trial Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested

NIHR HTA programme2006

116. The efficacy of antidepressants and various psychotherapies as adjunctive treatments for irritable bowel syndrome (IBS).

The efficacy of antidepressants and various psychotherapies as adjunctive treatments for irritable bowel syndrome (IBS). The efficacy of antidepressants and various psychotherapies as adjunctive treatments for irritable bowel syndrome (IBS). | National Guideline Clearinghouse Search Sign In Username or Email * Password * Remember Me Don't have an account? Guideline Summary NGC:005058 This guideline summary has been withdrawn from NGC. Please update your bookmarks. View all withdrawn summaries

University of Texas at Austin School of Nursing, Family Nurse Practitioner Program2006

117. Herbal medicines for treatment of irritable bowel syndrome.

Herbal medicines for treatment of irritable bowel syndrome. BACKGROUND: Traditional herbal therapies have been used for a long time to treat gastrointestinal disorders including irritable bowel syndrome, and their effectiveness from clinical research evidence needs to be systematically reviewed. OBJECTIVES: To assess the effectiveness and safety of herbal medicines in patients with irritable bowel syndrome. SEARCH STRATEGY: We searched the following electronic databases till July 2004 (...) the components of randomisation, allocation concealment, double blinding, and inclusion of randomised participants. MAIN RESULTS: Seventy-five randomised trials, involving 7957 participants with irritable bowel syndrome, met the inclusion criteria. The methodological quality of three double-blind, placebo-controlled trials was high, but the quality of remaining trials was generally low. Seventy-one different herbal medicines were tested in the included trials, in which herbal medicines were compared

Cochrane2006

118. Effectiveness of the Chinese herbal formula TongXieYaoFang for irritable bowel syndrome: a systematic review

Effectiveness of the Chinese herbal formula TongXieYaoFang for irritable bowel syndrome: a systematic review Effectiveness of the Chinese herbal formula TongXieYaoFang for irritable bowel syndrome: a systematic review Effectiveness of the Chinese herbal formula TongXieYaoFang for irritable bowel syndrome: a systematic review Bian Z, Wu T, Liu L, Miao J, Wong H, Song L, Sung J J CRD summary The review assessed the Chinese herbal medicine TongXieYaoFang for irritable bowel syndrome. The authors (...) concluded that TongXieYaoFang together with other Chinese medicinal herbs has the potential to improve symptoms of irritable bowel syndrome more than conventional medicines. It is highly likely that the evidence reviewed was biased towards results in favour of TongXieYaoFang. Authors' objectives To evaluate the effectiveness of TongXieYaoFang (TXYF) with or without additional Chinese herbal medicines for the management of irritable bowel syndrome (IBS). Searching MEDLINE, EMBASE, the Cochrane Controlled

DARE.2006

119. Systematic review: the effectiveness of hypnotherapy in the management of irritable bowel syndrome

Systematic review: the effectiveness of hypnotherapy in the management of irritable bowel syndrome Systematic review: the effectiveness of hypnotherapy in the management of irritable bowel syndrome Systematic review: the effectiveness of hypnotherapy in the management of irritable bowel syndrome Wilson S, Maddison T, Roberts L, Greenfield S, Singh S CRD summary This was a generally well-conducted review that evaluated the efficacy of hypnotherapy in the management of irritable bowel syndrome (...) . Most of the included studies showed an improvement in clinical symptoms, suggesting a significant benefit of hypnotherapy. The authors' cautious conclusions are appropriate given the small size and poor quality of the evidence presented. Authors' objectives To review the available evidence on the use of hypnotherapy in the management of irritable bowel syndrome (IBS). Searching AMED, CINAHL, CISCOM, the Cochrane Library, EMBASE, MEDLINE, PsycINFO, TRIP and the Social Sciences Citation Index were

DARE.2006

120. A randomised controlled trial of self-help interventions in patients with a primary care diagnosis of irritable bowel syndrome

A randomised controlled trial of self-help interventions in patients with a primary care diagnosis of irritable bowel syndrome A randomised controlled trial of self-help interventions in patients with a primary care diagnosis of irritable bowel syndrome A randomised controlled trial of self-help interventions in patients with a primary care diagnosis of irritable bowel syndrome Robinson A, Lee V, Kennedy A, Middleton L, Rogers A, Thompson D G, Reeves D Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two self-help interventions for patients with irritable bowel syndrome (IBS) were examined. The first intervention consisted of a comprehensive self-help guidebook produced following a series of focus group meetings with other IBS

NHS Economic Evaluation Database.2006